Strong Earnings Propel Robust Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy JNJ?
Source: seekingalpha
- Earnings Beat: Johnson & Johnson reported Q1 non-GAAP EPS of $2.70, exceeding expectations by $0.02, with revenue of $24.06 billion reflecting a 9.9% year-over-year increase, surpassing estimates by $450 million, indicating strong market performance.
- Clear Growth Strategy: The company has raised its 2026 guidance to projected sales of $100.8 billion, representing a 7.0% increase, and adjusted EPS of $11.55, also up 7.1%, highlighting J&J's potential for growth and profitability in the coming years.
- Drug Approvals: J&J received approval for ICOTYDE, the first targeted oral peptide for plaque psoriasis, and the combination of TECVAYLI and DARZALEX FASPRO for relapsed/refractory multiple myeloma patients, reinforcing its leadership in oncology treatments.
- Technological Advancements: The launch of VARIPULSE Pro in Europe features a new pulse sequence that is five times faster, while the TECNIS PureSee intraocular lens has been approved in the U.S., showcasing J&J's ongoing commitment to innovation and competitive edge in medical technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 237.960
Low
190.00
Averages
218.50
High
240.00
Current: 237.960
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stocks Rally with Tech Leading Gains Amid Mixed Earnings Reports
- Tech Sector Surge: The Nasdaq index has risen for nine consecutive sessions, marking its longest winning streak since December 2023, indicating strong investor confidence in tech stocks, although the overall market is extremely overbought, warranting caution among buyers.
- Strong Earnings Guidance: Johnson & Johnson reported first-quarter results that exceeded expectations, with management raising its guidance for the year and projecting a path to double-digit growth in the coming decade, bolstering market confidence in its long-term growth prospects in immunology and oncology.
- JPMorgan vs. Goldman Sachs: JPMorgan's earnings significantly outperformed those of Goldman Sachs, with strong revenue from fixed income, currency, and commodities, highlighting its competitive edge in investment banking, while Goldman faced challenges that could impact its market position.
- Blue Owl's Successful Financing: Blue Owl raised $400 million in the bond market at a 6.5% interest rate, a significant victory that could alleviate redemption pressures, reflecting renewed market confidence in its software offerings after a recent bounce.
See More
Novo Nordisk Partners with OpenAI to Accelerate Drug Development
- AI Transformation Partnership: Novo Nordisk has formed a new partnership with OpenAI aimed at accelerating drug development, which is expected to bring new therapies to market faster, resulting in a pre-market stock increase of over 2.5%.
- Enhanced Data Analysis: CEO Mike Doustdar stated that OpenAI's advanced capabilities will enable the company to analyze datasets at previously impossible scales, thereby accelerating hypothesis testing and identifying potential treatment options.
- Market Competition Pressure: Although analysts have noted that Novo Nordisk faces challenges from slowing growth and increasing competition, this partnership could be a key factor in changing investor perceptions and enhancing the company's future market performance.
- Industry Impact: This initiative not only showcases Novo Nordisk's innovative capabilities in healthcare but also has the potential to lead the pharmaceutical industry towards an AI-driven research and development model, thereby improving overall industry efficiency.
See More
Johnson & Johnson Raises 2026 Earnings Forecast Amid Sales Growth
- Earnings Forecast Upgrade: Johnson & Johnson raised its 2026 adjusted earnings per share forecast to a range of $11.45 to $11.65, up from the previous range of $11.43 to $11.63, reflecting confidence in future growth despite a 52.4% decline in net profit in Q1.
- Significant Sales Growth: The company reported a 9.9% year-over-year increase in sales to $24.06 billion in Q1, showcasing strong performance in innovative medicines and medical technology, particularly with an 11.2% rise in innovative medicine sales, which lays a foundation for future market share expansion.
- Dividend Increase: The quarterly dividend was raised by 3.1% to $1.34 per share, resulting in an annualized dividend of $5.36 compared to the previous $5.20, indicating the company's commitment to shareholder returns even amid declining profitability, thereby boosting investor confidence.
- Future Outlook: Johnson & Johnson plans to conduct an Enterprise Business Review on December 8, 2026, aimed at further optimizing its business structure and enhancing operational efficiency to adapt to market changes and strengthen competitiveness.
See More
Strong Earnings Drive Robust Growth
- Earnings Beat: Johnson & Johnson reported a non-GAAP EPS of $2.70, exceeding expectations by $0.02, which reflects the company's ongoing improvement in profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved $24.06 billion in revenue for the first quarter, surpassing market expectations by $450 million, indicating strong performance across multiple business segments, particularly driven by its pharmaceutical division, laying a solid foundation for future growth.
- Success in Multiple Myeloma: Johnson & Johnson's achievements in the multiple myeloma sector underpin its projection of $25 billion in growth by 2030, demonstrating the effectiveness of its strategic focus on innovative drug development.
- Stock Valuation Analysis: Despite the recent rally in stock price, analysts believe Johnson & Johnson's shares may still be undervalued, suggesting that investors should consider holding for long-term gains based on its strong financial performance and growth potential.
See More
Johnson & Johnson Announces 3.1% Dividend Increase to $1.34
- Dividend Increase: Johnson & Johnson has declared a quarterly dividend of $1.34 per share, representing a 3.1% increase from the previous $1.30, which underscores the company's ongoing profitability and effective cash flow management, thereby enhancing investor confidence.
- Yield Information: The forward yield of this dividend stands at 2.25%, providing a stable return for investors, particularly appealing to income-seeking investors in the current market environment.
- Payment Arrangement: The dividend is payable on June 9, with a record date of May 26 and an ex-dividend date also set for May 26, ensuring that shareholders receive their earnings promptly, which may bolster shareholder retention.
- Market Reaction: The dividend increase aligns with strong first-quarter performance, and while market expectations for the future may vary, the dividend hike could support the stock price to some extent, reflecting the company's confidence in future growth.
See More
Johnson & Johnson Raises Guidance After Strong Q1 Results
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, exceeding market expectations by $450 million, and while adjusted EPS slipped approximately 3% YoY to $2.70, it still surpassed estimates by $0.02, highlighting robust performance in its cancer drug segment.
- Significant Contribution from Cancer Drugs: The multiple myeloma therapy Darzalex generated $3.96 billion, exceeding analyst projections of $3.84 billion, which helped the Innovative Medicine unit achieve $15.4 billion in revenue with approximately 11% YoY growth, showcasing J&J's competitive edge in the oncology market.
- Optimistic Future Outlook: J&J raised its 2023 sales and adjusted EPS guidance midpoint to $100.8 billion and $11.55, respectively, up from previous projections of $100.5 billion and $11.53, reflecting the company's confidence in future growth.
- Positive Market Reaction: Analyst Edmund Ingham welcomed J&J's earnings report, asserting that no other pharmaceutical company will generate more revenue than JNJ in 2026, and noted that the potential approval of Icotyde will further bolster shareholder confidence, indicating strong growth prospects ahead.
See More
Stocks Rally with Tech Leading Gains Amid Mixed Earnings Reports
- Tech Sector Surge: The Nasdaq index has risen for nine consecutive sessions, marking its longest winning streak since December 2023, indicating strong investor confidence in tech stocks, although the overall market is extremely overbought, warranting caution among buyers.
- Strong Earnings Guidance: Johnson & Johnson reported first-quarter results that exceeded expectations, with management raising its guidance for the year and projecting a path to double-digit growth in the coming decade, bolstering market confidence in its long-term growth prospects in immunology and oncology.
- JPMorgan vs. Goldman Sachs: JPMorgan's earnings significantly outperformed those of Goldman Sachs, with strong revenue from fixed income, currency, and commodities, highlighting its competitive edge in investment banking, while Goldman faced challenges that could impact its market position.
- Blue Owl's Successful Financing: Blue Owl raised $400 million in the bond market at a 6.5% interest rate, a significant victory that could alleviate redemption pressures, reflecting renewed market confidence in its software offerings after a recent bounce.
See More
Novo Nordisk Partners with OpenAI to Accelerate Drug Development
- AI Transformation Partnership: Novo Nordisk has formed a new partnership with OpenAI aimed at accelerating drug development, which is expected to bring new therapies to market faster, resulting in a pre-market stock increase of over 2.5%.
- Enhanced Data Analysis: CEO Mike Doustdar stated that OpenAI's advanced capabilities will enable the company to analyze datasets at previously impossible scales, thereby accelerating hypothesis testing and identifying potential treatment options.
- Market Competition Pressure: Although analysts have noted that Novo Nordisk faces challenges from slowing growth and increasing competition, this partnership could be a key factor in changing investor perceptions and enhancing the company's future market performance.
- Industry Impact: This initiative not only showcases Novo Nordisk's innovative capabilities in healthcare but also has the potential to lead the pharmaceutical industry towards an AI-driven research and development model, thereby improving overall industry efficiency.
See More
Johnson & Johnson Raises 2026 Earnings Forecast Amid Sales Growth
- Earnings Forecast Upgrade: Johnson & Johnson raised its 2026 adjusted earnings per share forecast to a range of $11.45 to $11.65, up from the previous range of $11.43 to $11.63, reflecting confidence in future growth despite a 52.4% decline in net profit in Q1.
- Significant Sales Growth: The company reported a 9.9% year-over-year increase in sales to $24.06 billion in Q1, showcasing strong performance in innovative medicines and medical technology, particularly with an 11.2% rise in innovative medicine sales, which lays a foundation for future market share expansion.
- Dividend Increase: The quarterly dividend was raised by 3.1% to $1.34 per share, resulting in an annualized dividend of $5.36 compared to the previous $5.20, indicating the company's commitment to shareholder returns even amid declining profitability, thereby boosting investor confidence.
- Future Outlook: Johnson & Johnson plans to conduct an Enterprise Business Review on December 8, 2026, aimed at further optimizing its business structure and enhancing operational efficiency to adapt to market changes and strengthen competitiveness.
See More
Strong Earnings Drive Robust Growth
- Earnings Beat: Johnson & Johnson reported a non-GAAP EPS of $2.70, exceeding expectations by $0.02, which reflects the company's ongoing improvement in profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved $24.06 billion in revenue for the first quarter, surpassing market expectations by $450 million, indicating strong performance across multiple business segments, particularly driven by its pharmaceutical division, laying a solid foundation for future growth.
- Success in Multiple Myeloma: Johnson & Johnson's achievements in the multiple myeloma sector underpin its projection of $25 billion in growth by 2030, demonstrating the effectiveness of its strategic focus on innovative drug development.
- Stock Valuation Analysis: Despite the recent rally in stock price, analysts believe Johnson & Johnson's shares may still be undervalued, suggesting that investors should consider holding for long-term gains based on its strong financial performance and growth potential.
See More
Johnson & Johnson Announces 3.1% Dividend Increase to $1.34
- Dividend Increase: Johnson & Johnson has declared a quarterly dividend of $1.34 per share, representing a 3.1% increase from the previous $1.30, which underscores the company's ongoing profitability and effective cash flow management, thereby enhancing investor confidence.
- Yield Information: The forward yield of this dividend stands at 2.25%, providing a stable return for investors, particularly appealing to income-seeking investors in the current market environment.
- Payment Arrangement: The dividend is payable on June 9, with a record date of May 26 and an ex-dividend date also set for May 26, ensuring that shareholders receive their earnings promptly, which may bolster shareholder retention.
- Market Reaction: The dividend increase aligns with strong first-quarter performance, and while market expectations for the future may vary, the dividend hike could support the stock price to some extent, reflecting the company's confidence in future growth.
See More
Johnson & Johnson Raises Guidance After Strong Q1 Results
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, exceeding market expectations by $450 million, and while adjusted EPS slipped approximately 3% YoY to $2.70, it still surpassed estimates by $0.02, highlighting robust performance in its cancer drug segment.
- Significant Contribution from Cancer Drugs: The multiple myeloma therapy Darzalex generated $3.96 billion, exceeding analyst projections of $3.84 billion, which helped the Innovative Medicine unit achieve $15.4 billion in revenue with approximately 11% YoY growth, showcasing J&J's competitive edge in the oncology market.
- Optimistic Future Outlook: J&J raised its 2023 sales and adjusted EPS guidance midpoint to $100.8 billion and $11.55, respectively, up from previous projections of $100.5 billion and $11.53, reflecting the company's confidence in future growth.
- Positive Market Reaction: Analyst Edmund Ingham welcomed J&J's earnings report, asserting that no other pharmaceutical company will generate more revenue than JNJ in 2026, and noted that the potential approval of Icotyde will further bolster shareholder confidence, indicating strong growth prospects ahead.
See More
